PAG
LUMO

Paladin Advisory Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Paladin Advisory Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,387
Closed -$17K – 240
2024
Q3 		$17K Hold
4,387
– – 0.01% 190
2024
Q2 		$9.93K Hold
4,387
– – 0.01% 190
2024
Q1 		$12.5K Hold
4,387
– – 0.01% 187
2023
Q4 		$14K Hold
4,387
– – 0.01% 187
2023
Q3 		$14.5K Hold
4,387
– – 0.01% 201
2023
Q2 		$14.5K Hold
4,387
– – 0.01% 206
2023
Q1 		$14.5K Buy
+4,387
New +$15.3K 0.01% 204
2022
Q2 		– Sell
-4,382
Closed -$35.1K – 551
2022
Q1 		$40K Buy
+4,382
New +$39.1K 0.03% 187

Paladin Advisory Group's LUMO Position: Q4 2024 in Review

Paladin Advisory Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 4,387 shares — an estimated $17K sold.

Paladin Advisory Group first reported a position in LUMO in Q1 2022 and held it in 8 quarters. The position peaked at $40K in Q1 2022. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.

  • Paladin Advisory Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Paladin Advisory Group sold 4,387 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $17K.
  • Paladin Advisory Group first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • Paladin Advisory Group's Lumos Pharma, Inc. Common Stock position peaked at $40K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.

Based on Paladin Advisory Group's 13F filing for Q4 2024, filed 23 Jan 2025.